Serologically, PBC-AIH overlap syndrome is generally defined by the presence of key autoantibodies of PBC and/or AIH, i.e. AMA and anti-SMA autoantibodies, and usually higher levels of transaminases and relative therapy resistance according to the Paris criteria (51). The gene discussed is SMN1; the disease is overlapping connective tissue disease.